FREE Webinar - Advances in High Throughput Formulation Screening
Wednesday 20th November 2013 at 3 pm GMT, 4 pm CET, 10 am EST In response to the challenges of new product formats and increased regulatory scrutiny, the early developability of biotherapeutic candidates based on stability and formulation characteristics is becoming ever more important. This interactive webinar, brought to you by Avacta Analytical and Synthon Biopharmaceuticals, will address the themes and challenges in this area. Read more:
FREE Webinar - Advances in High Throughput Formulation Screening
Wednesday 20th November 2013 at 3 pm GMT, 4 pm CET, 10 am EST
In response to the challenges of new product formats and increased regulatory scrutiny, the early developability of biotherapeutic candidates based on stability and formulation characteristics is becoming ever more important. This interactive webinar, brought to you by Avacta Analytical and Synthon Biopharmaceuticals, will address the themes and challenges in this area.
The webinar will demonstrate how high throughput protein thermal stability analysis is widely used as a predictive tool to accelerate formulation development and candidate selection, or to optimise processing conditions downstream. It will focus on the formulation of a monoclonal antibody and the capabilities of high throughput screening to predict degradation, characterise stability and enhance workflows, as well as offering a case study in an industrial setting.
Click here to learn more and to register.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
